T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...